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Abstract 
Background: Adverse drug events (ADEs) are a significant cause of morbidity and mortality in 
older adults (age ≥ 65). Polypharmacy and potentially inappropriate medications (PIMs) are 
especially prevalent in this population and are a notable contributing risk factor for ADEs. 
Research demonstrates that comprehensive medication reconciliation that includes evaluation of 
both the risks and benefits of medications, in conjunction with deprescribing practices, can 
reduce PIMs; therefore, reducing ADEs.  
Purpose: The aim of this quality improvement project was to empower clinicians to deprescribe 
current medications that are inappropriate, as well as reduce the rate of newly prescribed PIMs 
among patients age ≥ 65 in the primary care setting by establishing a multi-modal educational 
intervention. 
Methods: A detailed educational program that incorporated evidence-based resources composed 
of the American Geriatrics Society (AGS) 2019 Beers Criteria®, PIMs, and deprescribing was 
introduced to 88 clinicians in a large academic, urban-based general internal medicine primary 
care clinic. Data was collected through pre-post intervention surveys to assess provider 
knowledge, prescribing practices, and self-efficacy in deprescribing. A retrospective medication 
chart review then assessed actual trends of prescribed PIMs in the clinic. 
Results: The 34 clinicians who completed each survey demonstrated an increased knowledge of 
AGS Beers Criteria® medications and reported a greater frequency in medication reconciliation 
performance. Notably, a paired t-test was performed to measure 13 providers’ reported self-
efficacy deprescribing; and each participant’s response improved post-intervention.  
Conclusion: Proper medication safety standards in older adults is a complex issue that requires 
significant education in order for clinicians to adopt informed prescribing practices, thus ongoing 
provider education and evaluation are recommended. This multi-modal educational intervention 
is feasible for implementation in various healthcare settings to expand provider knowledge. 
Keywords: deprescribing, polypharmacy, older adult, potentially inappropriate 
medications, Beers Criteria®, provider education, nurse-led intervention 
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In Beers We Trust: Using Deprescribing Tools to  
Reduce Inappropriate Polypharmacy in Adults Age ≥ 65 
The population of older persons in the United States is rapidly growing as the baby 
boomers age towards retirement. Older adults, recognized as those age ≥ 65, sustain a number of 
physiological age-related changes that require specialized knowledge and care, unique from their 
younger cohorts. Therefore, prescribers must be educated on age-related considerations that alter 
pharmacokinetics and pharmacodynamics of medications in order to prevent adverse drug events 
and manage a safe medication regimen in older persons. Using this knowledge, comprehensive 
medication reconciliation that utilizes deprescribing practices at primary care visits can reduce 
inappropriate polypharmacy in older adults, thus improving their quality of care, health safety, 
and outcomes.  
Background 
 According to the United States Census Bureau (2018), all baby boomers will be older 
than age 65 by the year 2030 and represent over 20% of the population. The U.S. Department of 
Human and Health Services has recognized the need for specialized care of older adults and has 
dedicated an objective of Healthy People 2020 to “improve the health, function, and quality of 
life of older adults.” Medication safety is an important aspect of quality care in the health 
management of older adults. Multi-morbidity of chronic illness has led to an increase in use of 
prescription drugs; and during the past 30 years, the percentage of older adults who report taking 
five or more prescription drugs has risen by 28.4% (Dills, Shah, Messinger-Rapport, Bradford, & 
Syed, 2018). Additionally, medication safety has been recognized as a 2019 National Patient 
Safety Goal by the Joint Commission with an emphasis on frequent and accurate medication 
reconciliation.  
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 It is well known that physiologic reserves decrease as we age; and this leads to a greater 
susceptibility to disease. Higher incidence of disease demands an increased need for 
pharmacological management. Consequently, older adults are often prescribed multiple 
medications, which poses a great risk for both drug-drug interactions and adverse drug reactions. 
Notably, the older adult experiences a decline in both renal and hepatic function, as well as an 
increase in proportion of body fat relative to skeletal muscle (Rochon, 2019). This leads to 
longer half-lives of medications and subsequently increased plasma drug concentrations due to 
decreased drug clearance and larger drug storage reservoirs. Many medications are affected by 
these alterations in the older adult physiology and therefore are referred to as potentially 
inappropriate medications (PIMs) (Fick et al., 2019). 
Guidelines have been created to identify potentially inappropriate medications in older 
adults, most notably the Beers Criteria® published by the American Geriatric Society (AGS). 
These criteria were originally created in 1991 by Mark H. Beers, MD and his colleagues to 
decrease the use of harmful medications in nursing home residents (Terrery & Nicoteri, 2016). 
Mark Beers defined PIMs in the criteria as “medications that pose greater risks than they provide 
in therapeutic value or those medications for which a safer alternative is available” (Ammerman, 
Simpkins, Warman, & Downs, 2019, p. 115).  Since the creation of the Beers Criteria®, these 
guidelines have grown exponentially as a resource for clinicians, educators, researchers, 
healthcare administrators, and regulators (AGS, 2019). To remain updated on the latest research, 
an interdisciplinary expert panel updates the criteria on a three-year cycle. The goal of the Beers 
Criteria® is to “improve the care of older adults by reducing their exposure to PIMs that have an 
unfavorable balance of benefits and harms compared with alternative treatment options” (AGS, 
2019, p. 2). There are five categories within the publication: medications that are potentially 
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inappropriate in most older adults, those that should typically be avoided in older adults with 
certain conditions, drugs to use with caution, drug-drug interactions, and drug dose adjustment 
based on kidney function (AGS, 2019). The Beers Criteria® is an invaluable resource for 
prescribing clinicians to ensure the utmost safety of their older adult patients, especially those 
who take numerous medications.  
The use of multiple medications by one individual is generally referred to as 
polypharmacy, and it is often described as the use of five or more medications (Chou, Tong, & 
Brandt, 2019); however, the exact “number of medications” that polypharmacy refers to varies. 
Because there is no standardized consensus on a definition, it is necessary for each individual 
study involving polypharmacy to specifically define the term in relation to their research. 
However, Molokhia and Majeed (2017) have taken the definition a step further and state that it is 
a “crude measure” (p. 2) to base the definition of polypharmacy simply on number of 
medications, for it does not take into account the possible benefits that the patient is receiving 
from multiple medications. Therefore, polypharmacy can be further defined as either appropriate 
or problematic (Molokhia & Majeed, 2017). Appropriate polypharmacy is when medications for 
multiple conditions are being optimized or prescribed on best available evidence, while 
problematic (inappropriate) polypharmacy is when the patient is prescribed multiple medications 
but does not receive the intended benefit (Molokhia & Majeed, 2017).  
 Inappropriate polypharmacy and PIMs increase the risk for adverse drug events (ADEs). 
An adverse drug event is defined as a “harm experienced by a patient as a result of exposure to a 
medication” (Agency for Healthcare Research and Quality [AHRQ], 2019). Adverse drug events 
are a major public health issue for older adults (Gray et al., 2018) and increase the likelihood of 
unplanned hospitalization in older adults (Zullo, Gray, Holmes, & Marcum, 2018). According to 
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the AHRQ (2019), ADEs account for nearly 700,000 emergency department visits and 100,000 
hospitalizations each year. In older adults, PIMs are also associated with confusion, falls, and 
mortality; and inappropriate medication use increases risk of morbidity, mortality, and health 
care costs (Zullo et al., 2018). Improving the appropriate use of polypharmacy and minimizing 
potentially inappropriate medications will optimize medication management in the older adult, 
thus supporting positive patient outcomes, health safety, and improved quality of life. 
Problem Statement 
Adverse drug events (ADEs) are a major health concern in adults age ≥ 65. This 
population experiences age-related physiological changes that increase their risk to sustain 
ADEs. This risk is exacerbated by the prescription of potentially inappropriate medications 
(PIMs) and inappropriate polypharmacy. Many healthcare providers have limited knowledge of 
deprescribing tools that can reduce the prescription of PIMs. Therefore, providers must be more 
knowledgeable and prudent in their prescribing practices, perform regular medication 
reconciliation, and utilize deprescribing to prevent adverse drug events in the older adult 
population. 
Organizational “Gap” Analysis of Project Site 
Before the onset of this quality improvement project, there was no standard for 
medication reconciliation and deprescribing in the primary care setting of the internal medicine 
clinic where this project was being implemented. Providers (nurse practitioners and physicians) 
perform a simplified medication reconciliation at the beginning of each visit to assess adherence. 
Providers do not, however, have a method for completing a comprehensive safety assessment for 
patient medication regimens that consistently evaluates risk and benefit at each visit. 
Additionally, there is no required formal education on medication safety in the older adult. There 
REDUCING INAPPROPRIATE POLYPHARMACY 9 
are no geriatricians in this clinic, and all older adults are treated by primary care providers with 
general medical training. While care of older adults should be a critical part of medical education 
of both physicians and nurse practitioners, the degree of experience between various providers is 
unknown. Therefore, this project sought to address this gap and provide education on 
inappropriate polypharmacy to promote safe prescribing practices in the clinic, as it is a global 
health problem.  
Review of the Literature 
Despite overwhelming evidence of the harmful effects of PIMs in the older adult, many 
clinicians are still prescribing them without first considering safer alternatives. The purpose of 
this critical appraisal of research was to evaluate these current prescribing practices and cite 
evidence-based interventions to reduce polypharmacy and preventable ADEs in the older adult.  
Search Process 
An extensive search of the literature was conducted using CINAHL, PubMed, Google 
Scholar, and the Cochrane Library. Inclusion criteria were articles published between 2014-2019, 
primary care setting, older adults (age ≥65), English language, peer reviewed, and any author is a 
nurse. Articles were not limited to just within the United States, and in fact much of the strong 
literature came from outside the country. Exclusion criteria were articles not written in English, 
acute care setting, and journals that are not peer reviewed. Search terms included: medication 
safety, older adult, adverse drug event, polypharmacy, potentially inappropriate medication, 
Beers Criteria®, medication reconciliation, deprescribing, primary care, intervention, meta-
analysis, literature review, and randomized controlled trial. Search criteria were expanded to 
include authors of all disciplines which resulted in beneficial information from both physicians 
and pharmacists. Additional resources were found using references of relevant articles. 
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 The literature was analyzed using the Johns Hopkins Nursing Evidence-Based Practice 
appraisal tool for level of evidence and quality (Newhouse et al., 2005). Each article was 
assigned an evidence level between I and V and an evidence quality grade of A (high quality), B 
(good quality), or C (low quality). This critical appraisal of research focuses on levels I and II; 
however, the intervention of this project is centered around evidence-based guidelines for 
deprescribing that were rigorously developed by experts from the Bruyère Research Institute in 
Ottawa, Canada (Level IV). The objective of this review was to explore interventions used to 
reduce potentially inappropriate medications in older adults with an emphasis on deprescribing 
tools and/or provider education. 
Critical Appraisal of Research  
 Adverse drug event reduction. One of the highest quality pieces of evidence we have 
exploring interventions to reduce ADEs is the latest update from the Cochrane Database of 
Systematic Reviews (Level IA) (Rankin et al., 2018). The review is expansive and includes uni-
faceted and multi-faceted interventions targeting polypharmacy in all settings (not only in 
primary care). These interventions include educational programs for providers, pharmacist-led 
medication review, and computer decision support. Primary outcomes measured in this 
systematic review were medication appropriateness, potentially inappropriate medications, 
potential prescribing omissions, and hospital admissions. Secondary outcomes included 
medication-related problems, adherence to medication, and quality of life. Each of these 
measures is specifically defined in the review.  
 Unfortunately, among 32 studies examined in this systematic review, no consistent 
intervention had a significant effect on medication-related problems, and the authors refer to the 
combined evidence as “rather weak” (Rankin et al., 2018, p.29). While this was a high quality 
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search, the results it yielded were not fruitful in supporting an intervention to improve the use of 
appropriate polypharmacy in older people. It should be noted that this Cochrane Database 
systematic review includes studies published through February 2018 and further research has 
been established since its publication which will be noted in this critical appraisal of research.  
 A recent meta-analysis published by the Journal of the American Geriatric Society after 
the release of the Cochrane review was more conclusive in its findings on interventions to reduce 
adverse drug reactions in older adults (Level IA). Authors Gray et al. (2018) reviewed 13 
randomized controlled trials involving 6,198 older adults. The study categorized interventions as 
pharmacist-led, health professional-led, and technology-based; and these interventions consisted 
of chart review and patient interview/ survey/ questionnaire. This vigorous review determined 
that intervention groups were less likely than the control group to experience adverse drug 
events. Gray et al. (2018) ultimately reported interventions aimed at medication optimization 
would thus reduce the risk for ADEs in older adults. Although this is a rather generalized 
statement made by the authors, it supports further research aiming to tailor more precise 
interventions for the aforementioned goals.  
 Medication reconciliation. Fundamentally speaking, to decrease adverse drug events 
one must first reduce the drugs that are the culprits of said events. One method to do this is 
through comprehensive medication reconciliation with risk/ benefit assessment of each 
individual medication in the patient’s regimen. While this is more challenging in older adults 
with more medications, it is increasingly important because each medication has the ability to 
not only interact undesirably in the body, but also in combination with concurrently taken 
medications. 
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 Although many interventions studied in the literature involve chart/ medication review, 
thorough medication reconciliation is often a challenge in itself for providers. Wolff, Nowacki, 
Yeh, and Hickner (2014) performed a randomized controlled trial to test two interventions to 
improve the medication review process (Level IB). Patients were either provided a printed copy 
of their current medication list at check-in, or their medication review began with an open-ended 
question, or neither or both of these interventions. The study concluded that while alone neither 
intervention improved medication list agreement, this may be beneficial in a multistep protocol 
aimed at improving medication reconciliation in the primary care setting (Wolff et al., 2014). 
This trial also emphasized the importance of the patient’s role in medication reconciliation as a 
shared-decision making process. 
 Two well-executed quality improvement projects (Level IIA) supported medication 
review as an effective method for improving quality of care in the older adult population 
(Stuckey, Henriksen, Singh, Dawson, & Waterson, 2018; Vejar, Makic, & Kotthoff-Burrell, 
2015). Stuckey et al. (2018) performed a prospective quality improvement project over a three-
month period in which patients age ≥ 65 with one or more high risk medication were contacted 
for medication review. This involved an in-person appointment for 40 minutes with a pharmacy 
team and 20 minutes with an interprofessional team to discuss recommendations/ interventions. 
The study resulted in a decrease from 42 to 28 high risk medications in the sample representing a 
33% reduction. While the project’s sample size was not large, its results support medication 
reconciliation with both patient shared-decision making and pharmacist collaboration. In contrast 
from other studies, this intervention did not take place at the average primary care visit, but at a 
separate visit dedicated to medication management. Based on specificity of a targeted visit, this 
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has great potential to make a significant difference in reduction of PIMs and inappropriate 
polypharmacy.  
Vejar et al. (2015) performed a pre- and post-group analysis with the aim of reducing 
ADEs caused by inappropriate drug management. Their four specific outcome goals were: 
improving medication reconciliation documentation; increasing the number of patients that 
“brown-bag” medication for clinical visits; reducing use of high-risk over the counter (OTC) 
medications; and reducing duplicate medication therapy. “Brown-bagging” is a practice where 
patients physically bring all of their medications from home to clinic so that they can be 
reviewed in person with their provider. This is helpful for some patients to have a visual aid of 
what medications they are actually taking. The patient may also be taking OTC supplements that 
are not listed in their medication lists that providers are unaware of; and these may have 
dangerous interactions with their prescribed medications. While reviewing medications in 
person, the provider is given a better understanding of the patient’s health literacy and can make 
an informed decision while measuring risk and benefit of each medication. Providers can even 
physically take away the medications they have deprescribed so that patients may not be 
confused with changes to their regimen. In the study by Vejar et al. (2015), interventions 
including provider education, patient education, patient questionnaires, written literature/ flyers, 
and pharmacist collaboration collectively improved the medication management of older adults.  
Provider education and pharmacist collaboration. Providers must be educated on the 
dangers of PIMs and inappropriate polypharmacy in older adults so that they can actively work 
towards prevention and deprescribing. With knowledge of the Beers Criteria®, providers can 
utilize prudent decision making when prescribing medications to this population. As a result, 
research is needed on interventions that target the education of healthcare providers on PIMs in 
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order to decrease the incidence of their prescription in older adults. Often, clinical pharmacists 
can be involved in this education process by sharing their expertise with providers. A 
randomized controlled trial of 503 patients (Level IA) was performed in Spain where an 
intervention group underwent medication review by a pharmacist-led group who made 
suggestions to the prescribing provider (Campins et al., 2017). Ultimately the intervention 
proved successful at reducing potentially inappropriate medications, although in this particular 
study it did not reduce emergency visits and hospitalizations of polymedicated older adults 
(Campins et al., 2017).  
Numerous intervention studies found in this literature review involved close collaboration 
with a clinical pharmacist and/or electronic medical resources which strengthened results. 
Unfortunately, these resources are often not available in the primary care setting and further 
research is needed to establish positive outcomes managed solely by providers. 
Deprescribing. Deprescribing interventions have shown the most improvement in 
reduction of potentially inappropriate medications as this is the direct practice of discontinuation. 
The concept of “deprescribing” was first introduced in 2003 in an Australian hospital pharmacy 
journal (Reeve, Gnjidic, Long & Hilmer, 2015). A systematic review (Level IA) by Reeve et al. 
(2015) explored the emerging definitions of “deprescribing” with the aim of establishing a 
standardized description to be used in future research. These authors proposed the following 
definition “Deprescribing is the process of withdrawal of an inappropriate medication, 
supervised by a health care professional with the goal of managing polypharmacy and improving 
outcomes” (Reeve et al., 2015, p. 1254).  
Effects of deprescribing. The first comprehensive systematic review of deprescribing 
interventions was published in the British Journal of Clinical Pharmacology by Page, Clifford, 
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Potter, Schwartz, and Etherton-Beer (2016). This robust meta-analysis (Level IA) studied the 
feasibility and effects of deprescribing processes on mortality and health of older adults. 
Secondary outcomes evaluated were adverse drug withdrawal events; psychological and physical 
health outcomes; quality of life; and medication usage (successful deprescribing, number of 
medications prescribed, potentially inappropriate medication use) (Page et al., 2016). Ultimately 
their review of deprescribing studies concluded that patient-specific interventions to reduce 
polypharmacy may improve longevity, and they can be achieved without adverse changes in 
health outcomes and quality of life.  
A systematic review of randomized controlled trials (Level IA) analyzed literature 
involving patients with chronic medical diseases to evaluate the impact of deprescription on 
reducing medication burden in the primary care setting (Dills et al., 2018). Consistent with other 
literature, this systematic review found successful deprescription and reduction of polypharmacy 
through educational interventions, patient-specific interventions, and pharmacist-physician 
collaboration (Dills et al., 2018). This study included patients age ≥ 18 rather than just older 
adults, although it is unclear if this would have affected the conclusions of the study. It is 
important to note, however, that the review suggests some negative implications for 
deprescription including expensive intensive interventions by clinicians; lack of expected 
outcomes (i.e. improved fall rate, cognition, lower hospital admission rate, etc.); or having 
unexpected adverse outcomes that affect patient quality of life. Further research is needed, 
although it is likely that the benefits of deprescription will outweigh the risks or lack of positive 
outcomes. 
Deprescribing tools. Since providers face many challenges towards improving 
inappropriate polypharmacy and deprescribing, it is crucial that they have as many tools as 
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possible to facilitate changes for safer prescribing practices. The Bruyère Research Institute in 
Ottawa, Canada has created numerous evidence-based resources to aid providers in 
deprescribing. A group of experts created deprescribing guidelines using sound methodology 
through a national modified Delphi consensus process (Level IVA) (Farrell, Pottie, Rojas-
Fernandez, Bjerre, Thompson, & Welcoh, 2016). Rigorous systematic reviews of drug classes, 
effectiveness, and deprescribing trials were performed to identify context for informed 
recommendations and guideline development. The Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) system was used to synthesize evidence and create 
deprescribing practice guidelines and specific algorithms for three drug classes: proton-pump 
inhibitors (PPIs), benzodiazepine receptor agonists (BZRAs), and antipsychotics (Farrell et al., 
2016). Algorithms for antihyperglycemics and cholinesterase inhibitors (ChEIs)/ memantine 
were also created by this institute; however, they were not utilized in this project. 
Further research (Level IIIA) from the Bruyère Research Institute evaluated 
implementation of their deprescribing guidelines in six practice sites (three in long-term care and 
three in primary care). Qualitative analysis of a survey administered at sequential points before, 
during, and after the implementation concluded that these guidelines appeared to increase 
clinicians’ self-efficacy in deprescribing medications based on the drug-specific algorithms 
(Farrell et al., 2018). When providers possess evidence-based knowledge and guidelines, they are 
more comfortable deprescribing potentially inappropriate medications when faced with various 
barriers in practice. 
Summary 
 There is extensive literature discussing the dangers of inappropriate polypharmacy and 
potentially inappropriate medications in the older adult. While much of the literature studying 
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interventions is not linked directly to patient outcomes including adverse drug events; many 
studies have led to decreased inappropriate polypharmacy and PIMs. Provider education is 
crucial so they can have the tools to empower patients/ caregivers in a shared-decision making 
process. Prescribing clinicians can then safely modify the medication regimens of older adults to 
reduce likelihood of drug interactions to prevent adverse outcomes. 
 Deprescribing potentially inappropriate medications by performing a comprehensive 
medication reconciliation is an effective method for reducing preventable adverse drug events. 
Deprescribing algorithms can be implemented in the primary care setting to guide prescribing 
practices and improve quality of care for older adults. It is crucial that providers are educated in 
the dangers of PIMs in older adults and are given deprescribing tools to reduce inappropriate 
polypharmacy. Specific evidence-based clinical practice guidelines and algorithms can ensure 
consistent practice for proper deprescribing and medication management of older adults in 
primary care. 
Theoretical Framework  
 This project followed the Knowledge to Action Model (KTA) (Graham et al., 2006). 
There are two phases of this model – knowledge creation and action cycle (Appendix A).  This 
model is a straightforward framework for knowledge translation, therefore fits perfectly with the 
American Association of Colleges of Nursing (AACN) DNP Essentials (AACN, 2006). The 
2019 AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults is an 
important guideline that was created as a resource for prescribing practitioners, and it is the 
foundation of the knowledge component for this framework.  Expansion of this knowledge 
included extensive evidence surrounding PIMs and clinical tools to aid in deprescribing and safe 
medication management. The knowledge was dispersed to the providers using a multi-modal 
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approach of in-person and electronic presentation.  
The action cycle of this project evaluated providers’ prescribing patterns in relation to 
PIMs in older adults before and after the intervention. The providers performed the action of 
deprescribing that is addressing the problem of inappropriate polypharmacy by utilizing the 
knowledge of PIMs and ADEs in older adults. It is anticipated that providers will continue to 
build on this knowledge with their patients in practice which will support their future safe 
prescribing methods.   
Project Description 
Goals, Objectives and Expected Outcomes  
 The goal of this project was to empower prescribing healthcare clinicians to deprescribe 
and reduce the new prescription of potentially inappropriate medications in patients age ≥ 65 in 
the primary care setting using a multi-modal educational intervention. Objectives were that: 
 Primary care providers would receive comprehensive yet succinct education including 
written literature of potentially inappropriate medications in the older adult, the 2019 
AGS Beers Criteria®, and deprescribing tools/ algorithms 
 Primary care providers would perform a comprehensive medication reconciliation to 
evaluate the risk/ benefit of medications at the start of each visit with patients age ≥ 65 
 Primary care providers would utilize the deprescribing process and given tools during 
their medication reconciliation practice with patients age ≥ 65 
Expected Outcomes 
 Based on the pre-intervention data, upon post-intervention evaluation: 
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1. An increased number of providers would report that they performed a comprehensive 
medication reconciliation that evaluates the risk and benefit of each medication 
prescribed to patients age ≥ 65 at the majority of visits  
2. Clinicians that participate in the project would report frequent use of the provided 
deprescribing tool - either the general deprescribing process and/or drug-specific 
algorithms 
3. Upon evaluating actual medication and prescription data from the clinic during pre-post 
intervention periods, specified classes of PIMs would result in an increase in 
discontinuation and/or a decrease in new/ refilled prescription 
4. Primary care providers would demonstrate increased knowledge of potentially 
inappropriate medications in the older adult and the 2019 AGS Beers Criteria® 
5. Providers would express improved self-efficacy and positive satisfaction towards 
implementing the deprescribing process into their daily practice 
Project Design 
 This quality improvement project educated providers on potentially inappropriate 
medications in older adults and deprescribing methods for use during primary care visits. 
Education was dispersed primarily through email in addition to a “resource binder” located in the 
clinic. This DNP student was also present in clinic once per week to encourage use of the 
materials and answer questions. Outcomes were evaluated through both quantitative and 
qualitative data. Trends in the prescription and discontinuation of potentially inappropriate 
medications were evaluated using data from the electronic medical record system. Pre- and post- 
intervention surveys collected both quantitative and qualitative data from providers on their 
knowledge and self-efficacy in deprescribing practices. 
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Setting and Participants 
 This project was implemented in a general internal medicine (GIM) primary care clinic at 
a large urban-based academic medical center. Patients of all ages and demographics are seen at 
this clinic, but the project focused specifically on patients age ≥ 65. Permanent staff of the clinic 
include 20 attending physicians and three nurse practitioners (NPs). Small groups of medical 
residents rotate through the clinic every two weeks. This intervention targeted not only these 
small groups, but the entire cohort of 65 residents that will ultimately practice at the clinic at 
some point during the academic year. Eighty-eight total providers were offered to participate. 
Barriers  
Evidence supports a number of barriers to implementing deprescribing processes 
including awareness, inertia, self-efficacy, and feasibility (Anderson et al., 2014). Many 
providers are deficient in knowledge of the immense adverse effects of potentially inappropriate 
medications in the older adult. Therefore, they lack insight into the appropriateness of their own 
prescribing practices (Anderson et al., 2014). This lack of knowledge may also translate to a lack 
of self-efficacy in the provider’s confidence in their ability to deprescribe medications. 
Conversely, if providers do maintain awareness of the potential dangers of their practice, they 
may fear unknown consequences and therefore are resistant to change (inertia). Additionally, 
performing a comprehensive medication reconciliation on every patient to evaluate the risk/ 
benefit of every medication may seem like a daunting task that providers may not have the time 
for during short visits. The providers have many responsibilities for disease management in their 
patients, and altering medication regimens may not be a priority that gets addressed.  
More specifically to this project, the Bruyère Research Institute held a symposium in 
March 2018 to evaluate potential barriers and facilitators in implementing their deprescribing 
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guidelines/ algorithms into practice (Conklin, Farrell, & Suleman, 2019). This involved an 
interactive discussion of 107 participants from various disciplines including physicians, nurses, 
policy makers, public members, and others from around the world. The findings from the 
symposium are in line with the systematic review performed by Anderson et al. (2014), although 
they identified a number of additional barriers. These include: patient and caregiver resistance to 
change (on top of provider resistance); legal/liability concerns; financial structures and business/ 
profit-related motivations; lack of policy/ protocol; and lack of resources/ tools to improve the 
culture and practice of deprescribing (Conklin et al., 2019).  
Cost-Benefit Analysis 
 Implementing deprescribing has potential for massive cost savings to the organization. It 
is estimated that preventable ADEs in the Medicare population have led to annual direct costs 
exceeding $800 million (Stuckey, Henriksen, Singh, Dawson, & Waterson, 2018). The cost for 
patients is also significant. It was cited by Vejar, Makic, and Kotthoff-Burrell (2015) that a 
recent study estimated 8,000-12,000 deaths per year were related to ADEs. This project has 
minimal cost responsibility from the organization. The DNP student paid for quality printing 
services and purchased Pocket Beers Criteria® cards which are sold from AGS at $30 per 25 
cards. This intervention did not take extra time for providers; therefore, they did not need to be 
paid additional time. The education was incorporated into their standard care and information 
could be reviewed at any time. See budget table (Appendix B). 
Ethical Considerations/Protection of Human Subjects 
 The University of Massachusetts, Amherst (UMass) Internal Review Board determination 
for process of approval was obtained prior to initiating the DNP project. Since this is a quality 
improvement project, Institutional Review Board (IRB) consent from the clinical facility was not 
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required. All personal identifying patient and provider information in the medical records was 
omitted in the data reports aggregated by the Nursing Informatics team before quantitative data 
was reviewed by the DNP student. Additionally, pre- and post- intervention surveys remained 
anonymous. Each participant created a unique survey code so that trends between pre- and post- 
intervention could be assessed. The project provided educational tools and resources to providers 
in order to benefit patient outcomes using evidence-based research. No ethical risk was posed to 
patients as they maintained their standard care whether or not the provider chose to participate in 
the project.  
Methods 
Project Implementation  
All licensed independent practitioners in the GIM clinic were made aware of this quality 
improvement project in October 2019 through an introductory email from the DNP student. See 
simplified project timeline (Appendix C). Through collaboration with the medical residency 
director, this DNP student offered a 15-minute presentation at a weekly resident conference 
where all of the attending physicians, NPs, and the current resident subgroup partake.  A 
PowerPoint was presented to illustrate the project’s purpose and design. This presentation 
contained evidence-based research and statistics surrounding PIMs and ADEs in older adults, as 
well as information on the Beers Criteria®, polypharmacy, and general deprescribing. The 
concept of “deprescribing” was introduced as defined by the Bruyère Research Institute: 
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 The presentation addressed anticipated barriers to deprescribing and provided an open forum for 
discussion with participants on how to combat these barriers. At the end of the presentation, 
attendees were shown the link and a QR code to the pre-intervention survey (created from 
SurveyMonkey http://www.surveymonkey.com). Unfortunately, time did not allow for survey 
completion at this time, but a follow up email was sent to each provider including the survey link 
and reinforcing information for those who were unable to attend. 
 Initially it was planned that this in-person presentation would be delivered at various 
resident conference sessions not only in clinic, but throughout the hospital (which is attached to 
clinic) multiple times before the intervention began. This would target providers not only in 
clinic at the time of project initiation, but also those that would be ultimately rotating through at 
any point during the academic year. An in-person introduction would have ideally encouraged 
more survey responses from the large cohort of 65 residents. This became exceedingly difficult 
to coordinate because of the frequent rotations in small groups. The attending physicians that 
supervise the residents suggested the DNP student remain exclusively in the clinic to streamline 
the project. This was a more realistic endeavor for the timeline and purposes of this doctoral 
project. Interactions in clinic proved effective to meet current residents during the data collection 
period, and these interactions would ultimately be most important for quantitative analysis of 
prescribing patterns. Regardless of in-person interaction, all 65 residents were encouraged to 
participate via email and offered the electronic education and surveys. 
Educational Intervention 
The education modules were designed to highlight deprescribing algorithms and 
guidelines created by the Bruyère Research Institute in Ottawa, Canada originally found on 
https://deprescribing.org/. By utilizing these evidence-based tools in the educational intervention, 
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participants received tangible methods to aid in their deprescribing practice, in addition to 
extensive knowledge regarding PIMs in older adults. However, because these algorithms were 
developed internationally, they needed to be modified to comply with medication trade names 
available in the United States. As a result, the DNP student researched the medications listed on 
each algorithm to assess for inconsistencies. In accordance with the official modification policy 
from the Bruyère Research Institute, the three algorithms were adapted for U.S. validity.  
In December 2019, the educational intervention began. This first educational email 
discussed the importance of comprehensive medication reconciliation and addressed barriers to 
deprescribing. Attachments in the email included: 
 official AGS Beers Criteria® journal article (Fick et al., 2019) 
 editorial from the AGS on the “proper use of the Beers Criteria®” (AGS, 2019) 
 article introducing the deprescribing process (Endsley, 2018) 
 article discussing alternative medications to those listed in the Beers Criteria® 
(Hanlon, Semla, & Schmader, 2015) 
Additionally, each permanent provider in the clinic personally received an official pocket guide 
to the 2019 AGS Beers Criteria® which was purchased directly from the American Geriatric 
Society. Hard copies of the guideline were intended to supplement the providers’ learning and to 
be used as a convenient and accessible reference during practice. These were also distributed to 
many residents rotating through the clinic throughout the project. Extras were placed in the 
resource binders and providers were encouraged to obtain a copy of this valuable resource. 
 Beginning January 2020, providers were sent detailed educational lessons via email 
weekly for five weeks. The first three lessons focused on drug-specific classes based on the 
deprescribing algorithms created by the Bruyère Research Institute. These three medication 
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classes are: proton-pump inhibitors (PPIs), benzodiazepine receptor agonists (BZRAs), and 
antipsychotics (APs). Each lesson included: a PDF of the US-adapted algorithm (Appendix D) 
and a clinical practice guideline for the deprescription of the specific medication class: 
o proton-pump inhibitors (Farrell et al., 2017) 
o benzodiazepine receptor agonists (Pottie et al., 2018) 
o antipsychotics (Bjerre et al., 2018) 
 The body of the emails was intended to engage learners in the weekly topic for a quick 
review of the lesson at a glance. Additional attachments to the email offered extensive 
information and resources for further research, should the provider choose to broaden his/her 
learning. Participants also received high quality color copies of the algorithms as a supplemental 
resource for daily practice.  Furthermore, two resource binders containing all articles from the 
lessons and extra copies of algorithms were placed in each of the two precepting rooms where 
residents work during clinic. These binders were also easily accessible to the attending 
physicians and NPs who also use these rooms.  
The fourth lesson was dedicated to medications with anticholinergic properties and those 
to be used with caution with impaired renal function. These are two specific subsections of the 
Beers Criteria® that require special attention. There are not currently specific deprescribing 
algorithms for these medications, but other evidence and resources were provided.  
A fifth lesson was added at the end of the month to discuss some other important PIMs 
not previous covered. Antihyperglycemics, medications for cardiovascular disease, statins, 
aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and over the counter medications were 
addressed. Statin discontinuation for primary prevention in older adults is currently a hot topic in 
primary care medicine. HMG-CoA reductase inhibitors (statins) are technically not listed in the 
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Beers Criteria® because their side effect risk is not limited to older adults, and they are often 
appropriately prescribed in this population. However, they were included in this project because 
they may be inappropriate for certain patients due to increased risk and lack of benefit. There are 
several guidelines addressing statins for primary prevention; however, recommendations for 
stopping and starting the medication are discordant with age and clinical risk (Hawley et al., 
2019). Evaluating cardiovascular risk, functional status, and life expectancy may indicate that a 
statin can be safely discontinued as part of an individualized patient plan. 
These email lessons reinforced the process of deprescribing and provided extensive 
evidence of why these medications are categorized as a PIMs. This was intended to increase 
providers’ knowledge/ awareness on the benefits of deprescribing which can support their 
decision making for practice change. Originally, the education was going to focus on 25 specific 
medications from the Beers Criteria®; but after further research, it was more effective to discuss 
the medications in terms of class. This eliminated the possibility of provider bias towards certain 
medications and yielded more data. 
Measurement Instruments  
In order to measure the outcomes of this DNP project, both quantitative and qualitative 
methods were used. Pre- and post-intervention surveys were created by the DNP student to 
measure subjective data (Appendices E & F). The surveys assessed provider knowledge of the 
Beers Criteria® and polypharmacy, as well as their current prescribing practices in medication 
reconciliation and deprescribing. The self-efficacy portion of the survey was modeled after a 
survey created by the Bruyère Research Institute (Farell et al., 2018) where self-efficacy was 
defined as “one’s belief in their capability to carry out specific tasks… in this case, belief in your 
capability to carry out tasks related to deprescribing [under the following circumstances].”  This 
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original self-efficacy survey was created using the Delphi process with a panel of experts on the 
deprescribing guideline research team. Permission was given by Dr. Barbara Farrell of the 
Bruyère Research Institute to use a portion of the survey for the purposes of this DNP project, 
and thus will contribute to future validity and reliability testing of this tool.  
A post-survey was administered the week following completion of the educational 
intervention. This assessed the same information as the pre-survey, in addition to providers’ 
perception of the project and satisfaction with the interventions. Furthermore, objective data of 
prescription trends were measured through reports run from the electronic medical health record 
(EMR) system by the institution’s Nursing Informatics team.  
Data Collection Procedure  
Obtaining survey participation from providers was initially difficult, but it was enhanced 
through personal interactions in the clinic. The DNP student offered candy and a handout with 
the link/ QR code to the survey as a reminder. The QR code was intended as a user-friendly way 
for participants to complete the survey on their phone or on-the-go. Anecdotally, this method 
was well-received by the resident physicians. The same process was used for the post-survey. 
The Nursing Informatics team at the facility used an internal system to synthesize the 
medication data. A report was run with the following inclusion criteria: 
 date range: 30 days before project initiation 
 patient age ≥ 65 
 location: general internal medicine clinic 
 order action type: discontinue, cancel, void, modify, order, renew, resume, refill 
 action personnel position: (all were included - physician, resident physician, NP) 
 medication name 
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 medication dose 
The action “modify” was included in the criteria because the practice of decreasing or tapering 
doses falls under the definition of deprescribing as referenced earlier. Unfortunately, the 
electronic system used to gather data did not allow access to medication doses; therefore, we 
could not confirm that the modification of a medication was in fact a decrease rather than an 
increase. As a result, the “modify” and “medication dose” actions were eliminated. The report 
ultimately yielded data from the actions “discontinue,” “void,” and “order”. This same report 
was run for a date range of 30 days after completion of the intervention. 
Data Analysis  
Descriptive and inferential statistics were used to evaluate the trends in data before and 
after the intervention. Excel reports were obtained from SurveyMonkey 
(http://www.surveymonkey.com) for all individual responses from both surveys. Responses were 
then coded appropriately to input into SPSS Version 26 (IBM Corporation, 2019) for analysis to 
produce frequency tables. These were then translated to bar charts through Excel for data 
visualization of outcomes. The figures are presented to accommodate visual and accessibility 
needs. Colors vary in brightness/ contrast and are outlined in black to allow easier interpretation 
for color-blind or visually impaired individuals.  The self-efficacy portion of the survey was 
analyzed in SPSS Version 26 (IBM Corporation, 2019) through a paired t-test between 
individual providers that completed both the pre- and post-intervention survey.  
Additionally, the EMR medication reports gathered to determine prescriber trends were 
manually coded in Excel and evaluated by this DNP student. The code consisted of nine 
categories: proton-pump inhibitor, benzodiazepine receptor agonist, antipsychotic, 
anticholinergic, NSAID, statin, sulfonylurea, opioid, and other PIM. The medications were then 
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divided into sheets of either “ordered” or “discontinued” then sorted by class for visualization of 
frequencies. 
Exceptions 
Of the 88 providers in this large academic urban-based general internal medicine primary 
care clinic that were offered the educational intervention to improve medication safety and 
deprescribing, 41 providers participated in the pre-intervention survey (response rate = 46.6%). 
Seven of these responses were removed from the sample as they were incomplete. The survey 
should take at least six minutes to complete, and these individuals completed it in less than two 
minutes per the SurveyMonkey (http://www.surveymonkey.com) report; therefore, this was the 
exclusion criteria. The same process was used for the post-intervention survey which resulted in 
35 responses (response rate = 39.8%). Only one response was incomplete and removed, 
coincidentally leaving 34 valid responses for each the pre- and post-surveys. These were not 
necessarily the same individuals who decided to participate in both surveys, but through a unique 
code they provided, 13 responses were matched between the pre- and post-intervention surveys 
to evaluate trends in their individual deprescribing self-efficacy before and after the educational 
intervention.  
After analyzing the results from the knowledge section of the survey, famotidine, 
nifedipine, hydromorphone, and morphine were excluded due to the potential for confusion and 
inconsistency relevant to the educational intervention. Although H2 agonists have been removed 
AGS Beers Criteria® from the list of medications to avoid in patients with dementia or cognitive 
impairment; they are still included under the specific list to avoid in patients with delirium as a 
potential for disease exacerbation (AGS Beers Criteria® Table 3). The American Geriatrics 
Society (2019) made this change from the 2015 criteria because there was concern that this 
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would overly restrict options for management of reflux and other issues in this patient 
population, and it may intersect with the recommendation to avoid use of PPIs in older adults 
without valid indications (AGS, 2019). Learners less familiar with the Beers Criteria® would not 
be expected to recall this level of detail.   
Nifedipine was removed from the analysis because this medication is listed on the AGS 
Beers Criteria® Table 2 in its immediate release form due to high risk for hypotension; but it is 
safe for older adults in its extended release form. This was not explicitly covered in the 
education provided through this project and was not clearly indicated on this survey.  
Furthermore, narcotics are not listed in the general “avoid” list (AGS 2019 Beers Criteria® Table 
2), but they are listed in various sections to avoid in older adults with a history of falls/ fractures 
and to be avoided with concurrent use of three or more CNS-active medications. Additionally, 
newer evidence is showing increasingly harmful adverse effects in older adults when opioids are 
used in combination with gabapentinoids and benzodiazepines (AGS, 2019). Otherwise, the risks 
of narcotic medications are equal in persons of all ages, and pain management needs to be 
carefully addressed outside of these guidelines.  
Results 
Sample 
 The 34 providers who completed the pre-intervention survey included 19 resident 
physicians, 12 attending physicians, and three nurse practitioners with a mean of 6.5 years of 
experience (SD = 7.60). The 34 providers of the post-intervention survey included 20 resident 
physicians, 11 attending physicians, and three nurse practitioners with a mean of 6.47 years of 
experience (SD = 7.14). The 13 matched participants who completed both pre- and post-surveys 
included 7 resident physicians, 4 attending physicians, and two nurse practitioners with a mean 
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of 4.76 years of experience (SD = 4.06). Some participants chose not to designate a unique code 
on either survey, and there may have been other unknown paired results not included in this 
sample.  
Survey Results 
The survey was divided into three domains to evaluate provider’s knowledge of the Beers 
Criteria®, their current subjective prescribing practices of PIMs, and their self-efficacy in 
deprescribing (See Appendices E & F). All 34 responses were statistically analyzed for 
frequencies in the first two categories; and the third section matched the 13 responses of 
providers who completed both surveys for individual behavior patterns pre-post intervention.  
Knowledge  
To assess provider knowledge, the survey asked providers to identify from a list of 18 
medications which are classified on the AGS Beers Criteria® as general PIMs to avoid in older 
adults. Competency proved greater in identifying medications that are in fact appropriate for 
older adults, but knowledge varied between different classes of PIMs both pre- and post- 
intervention. See Figures 1 and 2 for variation of participants’ correct responses before and after 
receiving the educational lessons.  
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Figure 1: Participant knowledge of PIMs listed on the AGS 2019 Beers Criteria® 
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Figure 2: Participant knowledge of medications not listed on the AGS 2019 Beers Criteria® 
 
 Providers were also asked about the goals of the AGS Beers Criteria® to reduce adverse 
drug events/ drug related problems and improve medication selection/ medication use in older 
adults relative to which population and setting they pertain. In the pre-intervention group, 23 
providers (67.6%) correctly answered this question, and 11 providers (32.4%) answered 
incorrectly. In the post-intervention responses, 24 providers (70.6%) answered correctly and 10 
(29.4%) incorrectly.  
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Prescribing Practices  
To assess prescribing behaviors before and after the intervention, providers were asked 
three questions using a Likert Scale. The survey demonstrated an increase in frequency of 
medication reconciliation performance and increased use of the AGS Beers Criteria® after the 
intervention. However, overall frequency of reported intentional deprescribing decreased. 
Responses are reflected in Figure 3.  
 
Figure 3: Prescribing practices before and after intervention reported using the following 
questions: Q1 Do you perform a comprehensive medication reconciliation at the start of each 
patient visit by evaluating the risk and benefit of each individual medication the patient is 
taking? Q2 Do you consider intentionally deprescribing medications in older adults to reduce 
polypharmacy? Q3 Do you utilize the Beers Criteria® as a resource in your practice?  
 
Self – efficacy 
 On the electronic version of the survey, this section was displayed in a “sliding bar” 
format with a unipolar scale of 0 to 100 (0 = cannot do at all, 50 = moderately certain can do, 
100 = highly certain can do). Providers used this scale to self-report their confidence 
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deprescribing PIMs under 24 certain circumstances. Relative to the intervention, Tables 1 and 2 
display the means of these matched responses along with their variance, effect size (d), and 
significance (p). In each one of the 24 circumstances, participants reported an increase in self-
efficacy pre-post intervention.  As a result, overall self-efficacy was improved as demonstrated 
by the mean total scores from the 24 items (Pre: M = 56.11, Post: M = 66.01). 
Table 1 
Deprescribing Self-Efficacy Score Results (N=13) 
For a patient 65 years of age or older 
who is taking a PIM, I am able to: 
Pre (Mean, SD) Post (Mean, SD) Effect Size (d) 
1.Weigh the benefits vs. harms of 
continuing the PIM 
(70.08, 19.01) (77.54, 14.49) .7* 
2. Weigh the benefits vs. harms of 
deprescribing the PIM 
(66.00, 17.45) (78.00, 14.91) .8* 
3. Determine whether a non-
pharmacological intervention would 
facilitate deprescribing the PIM 
(61.77, 22.96) (72.38, 14.87) .7* 
4. Consider the patient’s preferences, 
care goals, and life expectancy in 
decided whether to continue or 
deprescribe the PIM 
(76.00, 21.42) (83.31, 10.36) .3 
5. Determine the best dosing approach 
to deprescribing the PIM 
(55.77, 26.13) (68.92, 20.26) .6* 
6. Develop a monitoring plan to 
determine the outcome of deprescribing 
the PIM 
(55.08, 27.29) (72.31, 17.54) 1.0** 
7. Negotiate a deprescribing plan for the 
PIM with the patient/ caregivers 
(65.23, 21.19) (72.92, 16.86) .5 
8. Monitor and follow-up to determine 
the outcome of deprescribing the PIM 
(65.31, 24.19) (76.08, 16.21) .4† 
9. Determine if PIM tapering should 
stop or if the PIM should be restarted 
(61.23, 25.04) (73.46, 19.28) .6* 
Overall Self-Efficacy Mean Pre: 64.05 Post: 74.99  
†p ≤ .10, *p<.05, **p<.01, ***p<.001  
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Table 2 
Deprescribing Self-Efficacy Score Results (N=13)  
For a patient 65 years of age or older, I 
am able to deprescribe a medication: 
Pre (Mean, SD) Post (Mean, SD) Effect Size (d) 
1. When I am concerned about adverse 
drug withdrawal events 
(65.69, 23.12) (74.92, 22.45) .4 
2. When I am concerned about 
exacerbations of the underlying 
condition the drug is being used to treat 
(62.23, 22.36) (70.69, 19.55) .2 
3. When disease-specific clinical 
guidelines recommend the use of a 
medication 
(53.38, 23.96) (63.62, 21.03) .4 
4. When the medication is coupled to 
performance indicators 
(53.23, 24.17) (62.08, 18.12) .4 
5. When I receive little support from 
colleagues for stopping or reducing 
medications 
(47.92, 22.04) (60.08, 17.11) .9** 
6. When I have too much work to do (49.08, 28.04) (60.00, 19.72) .3 
7. When I am concerned about damage 
to my provider-patient relationship 
(52.92, 22.56) (61.78, 17.83) .4 
8. When the patient is resistant to 
change 
(46.08, 18.09) (66.23, 11.20) 1.0** 
9. When the patient’s family/ caregivers 
are resistant to change 
(47.69, 17.75) (64.69, 12.84) .8** 
10. When there is no literature 
describing the effects of medication 
tapering or discontinuation 
(48.31, 21.48) (48.85, 16.96) 0 
11. When there is no guidance on how 
to taper or stop a medication 
(47.08, 22.70) (52.54, 16.72) .3 
12. When I am not the original 
prescriber of the medication 
(51.38, 21.07) (58.46, 24.98) .5† 
13. When the medication was prescribed 
by a specialist 
(40.23, 22.54) (49.38, 19.05) .4 
14. When I am unsure why the 
medication was started originally  
(46.54, 19.46) (57.08, 16.96) .6† 
15. When the medication is being used 
to treat an adverse effect of another 
medication 
(58.31, 25.14) (59.00, 24.67) .0 
Overall Self-Efficacy Mean Pre: 51.34 Post: 60.63  
†p ≤ .10, *p<.05, **p<.01, ***p<.001 
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After these numerical self-efficacy responses regarding certain circumstances, providers 
were then asked about their overall comfort deprescribing or adjusting dosages of PIMs, 
including those that they did not initially prescribe to the patient. These scores show the largest 
increase in those that are somewhat confident after the intervention, and a decrease in extremely 
confident and very confident as demonstrated in Figure 4.  
 
Figure 4: Overall confidence deprescribing PIMs before and after receiving the educational 
intervention. 
 
Medication Data Reports 
 The report samples of 30 days pre- and post- intervention were limited to this timeframe 
for the purposes of this scholarly project; therefore, the data was not substantial enough to 
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trends. The categories of PIMs identified most frequently on both the pre- and post-intervention 
medication reports (for either prescription or discontinuation) were PPIs, BZRAs, statins, and 
CNS depressants.  Objective data from these reports were inconclusive in determining true 
prescribing trends and/or if they had been influenced by the intervention. 
Discussion 
 Completion of this study demonstrated the true complexity of medication safety in older 
adults. Education on PIMs and deprescribing is an ongoing process as there is continually new 
evidence attributing to new knowledge. Furthermore, since there is much more to deprescribing 
than a clinical practice guideline or algorithm, it is a skill that requires a higher level of critical 
thinking and clinical aptitude. 
Evaluation of Results 
 There are a range of conclusions that can be inferred from the three domains of the 
survey and trends in prescribing patterns.  
Knowledge 
It is important to acknowledge the characteristics of the general internal medicine 
residency program where the study was conducted. As an academic practice, many of the 
attending physicians are also professors, and the residents undergo a rigorous education program 
simultaneously with their practice in clinic. The nurse practitioners have a high standard of 
practice as well, and one is a certified Adult/ Gerontological Primary Care Nurse Practitioner 
(AGPCNP). As a result, this sample of individuals may have a stronger baseline knowledge than 
providers in some other practices. However, it should be noted that none of the practicing 
physicians are certified geriatricians in this outpatient clinic.  
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 Of the nine medications that should have been identified as Beers Criteria® medications, 
the most significant improvement in knowledge was the identification of pantoprazole, a proton-
pump inhibitor, as a Beers Criteria® medication (expected outcome #4). Before the intervention, 
15 providers (44.1%) identified pantoprazole as a PIM on the Beers Criteria®, and after the 
intervention, 21 providers (61.8%) identified this correctly. Chronic use of proton-pump 
inhibitors (PPIs) is currently a particularly hot topic in primary care, and detailed education of 
potential side effects, medication related problems, and the latest evidence were included in the 
first education lesson of the series.  
Providers also demonstrated a reliable understanding that medications with 
anticholinergic properties and benzodiazepines are PIMs in older adults. The post-intervention 
correct response rates for diphenhydramine and diazepam were each 100%, although the baseline 
pre-intervention rates for both medications were 97.1%. Interestingly, although knowledge 
improved from before the intervention, ibuprofen was the least understood PIM on this list 
(correct response rate pre-35.3%, post-38.2%). Nonsteroidal anti-inflammatory drugs (NSAIDs) 
are listed on the AGS Beers Criteria® as potentially inappropriate due to their increased risk of 
gastrointestinal bleeding and/or peptic ulcer disease in high-risk groups (Beers Table 2). NSAIDs 
are also listed in Beers Table 3 as potentially inappropriate to those with chronic kidney disease 
stage 4 or higher (creatinine clearance <30ml/min). Furthermore, these medications are listed on 
Beers Table 5 as potentially inappropriate drug-drug interactions that should be avoided in older 
adults on warfarin or corticosteroids (oral or parenteral). Ibuprofen and other NSAIDs are 
common over-the-counter medications, and it is important to include these in detailed medication 
reconciliation at each patient visit. While there are in fact some appropriate indications for short-
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term use of NSAIDs, it is critical that these medications are identified as potentially 
inappropriate in older adults, especially for chronic use. 
The five medications measured in the sample that are not listed on the AGS Beers 
Criteria® (docusate, metronidazole, atorvastatin, metoprolol, acetaminophen) are widely 
prescribed drugs, and this may explain why there was limited change in knowledge through this 
intervention. Overall, providers demonstrated a firm comprehension of PIMs that would support 
safe medication management in older adult patients.  
Prescribing Practices 
The educational intervention encouraged providers to perform a comprehensive 
medication reconciliation at the beginning of each patient’s visit to evaluate for inappropriate 
polypharmacy and opportunities for deprescribing. This is a difficult task for any provider due to 
limited time during patient visits, especially among populations with multi-morbidity and 
increased age. After the intervention, 88.3% of providers reported they perform medication 
reconciliation either “frequently” or “almost always” (expected outcome #1). This project 
brought to light the importance of medication reconciliation as the first step of deprescribing. 
Additionally, after distribution of materials, 85.3% of participants reported use of the AGS Beers 
Criteria® at least “occasionally” during practice, which was an improvement from 72.8% pre-
intervention (expected outcome #2). Anecdotally, throughout the intervention, multiple providers 
verbally expressed their satisfaction in the utility of the AGS Beers Criteria® pocket guide in 
their day-to-day practice. Increased awareness and accessibility to evidence-based guidelines 
facilitated greater use of the material. 
Conversely, the objective results of providers’ survey responses reflected a slight 
decrease in frequency of their intentional deprescribing practices pre-post intervention. 
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Participants may have been overwhelmed with the amount of detail presented on the 
deprescribing process, thus lowering their intent to carry-out the practice. However, the 
frequency chart presented was derived from the entire sample (N=34) rather than solely the 
sample of matched pairs from whom we evaluated self-efficacy (n =13). As a result, the 
individuals that only completed one of the surveys may have had different baseline behaviors. 
Furthermore, despite the intervention, approximately 75% of providers reported considering 
intentional deprescribing either almost always or frequently. For a newer concept, this statistic is 
impressive, for it shows deprescribing is on the forefront of providers’ minds; and it confirms the 
need for further education to facilitate implementation. 
Self-efficacy 
According to Farrell et al. (2018, p. 19), self-efficacy is defined as “the belief that one is 
capable of organizing and completing actions to achieve specific challenges,” and it can also be 
understood as a provider’s level of confidence or comfort in deprescribing. The results of the 
self-efficacy section of the survey proved to be most interesting due to the statistical significance 
and effect size of the paired t-test between individual provider practices pre-post intervention. 
While the sample size of the paired results was smaller (N = 13), it should be emphasized that 
every single survey item demonstrated an increase in self-efficacy after the intervention, thus 
fulfilling the fifth expected outcome of the study. Effect sizes were interpreted using Cohen’s d 
(Cohen, 1988). 
The most notable report from the analysis was the increase in providers’ perceived ability 
to deprescribe PIMs even “when the patient/family/caregiver is resistant to change.” With newly 
acquired knowledge from the intervention, providers felt empowered to educate their patients to 
engage in the most appropriate shared-decision making processes. This also demonstrates that 
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these providers are well respected by their patients, and they feel confident that they can 
collaborate to make change even when there is uncertainty. The practitioners in this clinic have a 
high regard for relationship-based care which is vital to deprescribing.   
Additionally, the intervention had a notable statistically significant effect on providers’ 
perceived ability to “develop a monitoring plan to determine the outcome of deprescribing a 
PIM.” Providers were given tools/algorithms that were found useful for carrying out the process 
of deprescribing PIMs in their older adult patients. Deprescribing is a complex practice and 
requires thoughtful planning in order to execute successfully. Having evidence-based resources 
to guide this process is a key factor in not only initiating, but also maintaining safer medication 
regimens in older adults.  
Furthermore, providers expressed an increased self-efficacy deprescribing “when 
receiving little support from colleagues for stopping or reducing medication.” This is an 
interesting result because colleagues are seen to be incredibly supportive in this clinic. Perhaps 
the implementation of the project itself manifested as a source of support; therefore, providers 
felt more comfortable after project completion.  
Clinicians reported the highest levels of confidence regarding “patient preferences, goals 
and life expectancy” in both groups; however, the effect size is low suggesting this change may 
not have resulted from the intervention. This is not surprising, as the academic institution’s 
primary philosophy of care is that of the “whole person;” and it is expected as a standard for 
every practitioner. Deprescribing encompasses all of these domains in patient care, and assessing 
patient goals is a fundamental step in the process. Again, every single provider’s perception of 
their self-efficacy in deprescribing improved pre-post intervention, a truly remarkable result.  
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 Current Literature. Results from this survey were comparable to those from its model 
implemented by the original authors of the algorithms in their own self-efficacy survey (Farrell 
et al., 2018). While these researchers’ analysis was more complex over a larger time-series and 
in different care settings; the intervention of this DNP project was more intricate, including not 
only algorithms, but multi-modal evidence. Implementation of guidelines from Farrell et al. 
(2018) included onsite PowerPoint presentations of key guideline components along with the 
decision-support algorithms, as well as an opportunity to discuss implementation strategies. As 
mentioned, the in-person presentation component of the DNP project was limited; however, 
education included detailed topic summaries with supporting evidence, in addition to the 
algorithms and clinical practice guidelines. Response rates to this DNP project survey pre-post 
(46.6%, 39.8%) were higher than the original pilot in Canada over a four-part time-series 
(27.2%, 20.2%, 17.6%, 30.0%). The results of this DNP project are consistent with those from 
Farrell et al. (2018) who also saw an increase in self-efficacy for creating and implementing a 
deprescribing plan after administering evidence-based guidelines. 
Medication Trends 
 Analysis of the medication reports proved very challenging for a number of reasons. As 
mentioned, the timeline was limited for this project; therefore, the quantity of collected objective 
data was modest. The pre- and post-intervention data sets included only 21 actual clinic days (out 
of the 30 calendar days), and it was not possible to control for any patient-specific variables 
aside from age. Deprescribing is an incredibly individualized process that requires numerous 
unique considerations, and not all older adults meet the criteria. Pertinent information to 
determine the actual appropriateness of medications was not available including past medical 
history, kidney function, potential for drug-drug interactions, and life expectancy to name a few. 
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Since there are exceptions to the AGS Beers Criteria® and other medications considered 
potentially inappropriate, it is unfair to deem them all as unsafe without assessing other factors. 
Additionally, it would be unreasonable to expect a legitimate trend in prescription and 
deprescription based on the data acquired in this project; thus expected outcome #3 was unable 
to be determined.   
Challenges 
 As mentioned in the literature review, there were numerous anticipated barriers to this 
project, and many were observed. These included provider buy-in, resistance to practice change, 
and time constraint. Feasibility appeared to be the greatest challenge – both for project 
participation and for the practice of deprescribing. Resident physicians at this academic 
institution are engaged in a rigorous program that does not allow much time for participation in 
other activities. Therefore, it was especially difficult to engage participants in completing the 
surveys, particularly those with whom the DNP student could not interact in person. It was also 
challenging to coordinate scheduled presentations with the residency program leaders, as the 
residents were divided into several small groups throughout the hospital and greater health 
system. As a result, the project was modified to focus only on the providers present in clinic 
during the intervention period. While 88 providers still received the education, a smaller sample 
was used for data collection.  
Time constraint to complete the survey was a challenge. The survey was estimated to 
take around six minutes; however, many providers noted the survey was “too long,” which is not 
ideal for the demanding role of a clinician. Shortening the survey was considered, but the self-
efficacy portion was ultimately kept since it is in the process of becoming a validated tool 
(Farrell et al., 2018). Because of the length of the survey, many participants could have easily 
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misread questions and answered hastily, thus not truly representing their own prescribing 
behaviors and confidence deprescribing. Furthermore, it was of greater difficulty obtaining post-
intervention responses since the group was potentially desensitized to the emails. Preconceived 
notion of survey length may have also led to avoidance. As a result, 13 responses were matched 
out of the 34; nevertheless, this sample was still considerably valuable.  
There was also difficulty obtaining EMR data. It was initially thought that reports could 
be easily drawn from the system to view medication changes in patients age 65 and older within 
the clinic. The Nursing Informatics team had difficulty accessing this information, and there 
lacked a simple method to filter the exact data needed with multiple patient-specific variables for 
this project’s purposes. Consequently, a large data set was manually evaluated by the DNP 
student, but medication trends were not able to be statistically analyzed.  
Additionally, the DNP student experienced a challenge in modifying the drug-specific 
algorithms from the Bruyère Research Institute. This required considerable attention to detail, 
and the initial modifications submitted were found not to be comprehensive as a U.S. adaptation. 
Therefore, a resubmission was required to obtain the correct citation for approved use of the 
algorithms. Working with an outside source was an uncontrollable factor in the project, although 
the educational intervention was still executed in a timely manner.  
One interesting and unanticipated barrier was the new role of the DNP student in a 
primarily physician-run clinic. While there are three nurse practitioners actively working and 
well-respected within the clinic, it is not typical for a nurse practitioner student to be involved in 
medical education with the residents and other medical students. Therefore, this project 
introduced the unique role of a DNP student in the clinic. This novelty was surprising since the 
academic center is well-renowned for the latest innovations in medicine and nursing; however, 
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the physicians themselves had not encountered this role in their own practice. For the DNP 
student it was initially difficult to single-handedly introduce the role into practice, but 
implementing this project was an incredible first step in utilizing the DNP for clinical evidence-
based translation. More physical time in clinic interacting with the physicians allowed for greater 
understanding and increased respect of the DNP role.  
Strengths and Limitations 
There were several strengths of this DNP project. It was intricately planned to leave a 
significant impact on its participants. The topic of medication safety in older adults is an 
extremely important discussion, and there was a high need for attention in this clinic that lacks 
licensed geriatricians. It was beneficial to implement in an academic learning center because 
providers were privy to research and quality improvement projects. Furthermore, large effect 
sizes were extracted from the paired t-test results, signifying the intervention substantially 
influenced post-intervention self-efficacy data.  
There were also limitations to this project.  Since this educational intervention was not 
required learning, providers were likely not able to review all of the content concurrently with 
their already heavy load of responsibilities. Furthermore, the sample size of paired t-test results 
was relatively small (N = 13). Due to the scope of this quality improvement project as a DNP 
scholarly endeavor, there was limited time for implementation and analysis of results. With more 
time, these limitations could be addressed, and medication records could be reviewed over a 
larger time-series. This could better determine if the prescription and deprescription of PIMs in 
older adults treated in this clinic were significantly impacted by the intervention. It would also 
allow for more in-person presentations to encourage participation in surveys and teach key points 
from the education. This would also guarantee that more providers receive hard-copies of the 
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algorithms and pocket guide of AGS Beers Criteria®, which were both anecdotally deemed 
useful by other participants. 
Provider Feedback 
 During the pre-intervention period, many providers reported a need for tangible 
guidelines and strategies for deprescribing. They inquired how to better incorporate the AGS 
Beers Criteria® into practice and learn more specifics in degrees of contraindications for PIMs. 
Practitioners also emphasized a need for guidance on how to taper medications along with 
efficacious alternatives. Each of these points were introduced throughout the educational lessons 
to tailor their learning needs.  
 After the intervention, participants endorsed positive feedback on the project. Providers 
especially found the module on BZRAs helpful, namely processes for tapering these 
medications. This topic requires strong patient-provider collaboration; therefore, the patient must 
have a solid understanding of the process. Multiple patient education resources were also 
provided in the modules which facilitated patient buy-in of deprescribing. Additionally, 
participants demonstrated understanding of the importance of medication reconciliation. When 
asked the most important lesson gained from the educational intervention, one provider stated 
“medication reconciliation is a must for every visit.” This indicates the project was successful in 
emphasizing this crucial first step in deprescribing.  
Providers also delivered constructive feedback regarding the project. One attending 
physician commented on his survey, “I did not have time to review the materials because clinic 
and admin time are unfortunately packed.” Time constraints were a definite anticipated barrier 
for the project, but this is a factor that will take repetitive reinforcement to address. Fortunately, 
the intervention was set up through organized emails and the resource binder so that education 
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can be easily accessed when needed at any time. However, one participant did note “there were a 
lot of emails and it was difficult to follow along with each and every one.” This again attests to 
the complexity of the topic and need for further reinforcement of the education.  Providers did, 
however, find the material very useful. Two attending physicians expressed interest in using the 
patient education materials as standard handouts to use in practice and inquired of using links 
from www.deprescribing.com as “quick-text” for patient visit summaries. Furthermore, multiple 
participants suggested the use of more in-person presentation, thus affirming the importance of 
this component for the future.  
Clinical Implications 
 Clinics that care for older adults must employ a geriatrician or provider with additional 
training in gerontology.  There a clear need for this specialized education, even in centers known 
for providing exceptional standards of care. The age-related considerations for the geriatric 
population are immense, and it appears that many providers do not always prioritize this in their 
practice. Older adults are a unique and vulnerable population that require individualized care. 
They should be considered a specialized patient population similar to that of pediatric patients, 
although this is often overlooked in practice. Consequently, specialized classes in gerontology 
should be included in early training of healthcare providers (i.e. medical school, undergraduate 
nursing school), and then again during medical residency and nurse practitioner training. 
Unfortunately, this foundational education is not consistent with every prescribing practitioner, 
yet it is imperative for medication safety in advanced practice. Subsequently, the educational 
intervention would be advantageous if implemented as a continuing education opportunity for 
healthcare providers.  
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 Moreover, medication reconciliation must become a standard component of patient 
assessment. Similar to identifying “name and date of birth,” providers should identify which 
medications each patient is taking and utilize this information to formulate plans of care and 
future treatment recommendations. The potential for drug-drug interactions and drug-disease 
exacerbations is critical for the provider to account for in prescribing and deprescribing PIMs. 
The clinical implications of medication safety in older adults are profound and worthy of careful 
consideration.  
Future Recommendations 
 The intervention itself can be utilized as a training program or continuing education 
opportunity. This was a reliable pilot that can be exponentially developed for further research. It 
is unreasonable to cover every important topic under the realm of pharmacology, but provider 
education can be divided into a myriad of sectors. Using a pre-intervention survey geared 
towards identifying provider needs and interests may lead to more successful outcomes.  
Education can be divided by medication class or by deprescribing domain (provider knowledge, 
provider behavior, patient education, deprescribing tools, etc.). More research on education of 
PIMs will lead to improved clinical translation and will emphasize its necessity in practice.  
 Furthermore, studying patient-specific information may yield more definitive results in 
evaluating prescribing trends. By controlling for variables that affect medication appropriateness 
in different individuals, there will be more certainty on the utility of deprescribing resources. 
Time-series trends may show subtle but crucial trends in medication reconciliation. Moreover, 
completing a larger study that attains IRB approval to follow specific patients and prescribers 
will achieve higher specificity of results. The project can be easily scaled up to replicate in all 
healthcare settings including acute and subacute care. 
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DNP Essentials  
 This scholarly DNP project, In Beers We Trust, exemplified each of the American 
Association of Colleges of Nursing DNP Essentials (AACN, 2006) from its earliest stages of 
problem identification through its implementation and evaluation. The first AACN DNP 
Essential: Scientific Underpinnings for Practice is the crux of quality improvement. 
Inappropriate polypharmacy in older adults is a widely-known problem, and the extensive 
literature review immediately identified deprescribing as a promising intervention. Furthermore, 
the project relates directly back to the theoretical framework Knowledge-to-Action (KTA) 
(Graham et al., 2006). As described, a plethora of knowledge was provided throughout the 
intervention to deeply educate participating providers. Their validated self-efficacy in 
deprescribing depicted their action after the intervention. The straightforward direction of the 
KTA model aligned the project in a systematic process for education to practice.  
In Beers We Trust also illuminated AACN DNP Essential VII: Clinical Prevention and 
Population Health for Improving the Nation’s Health by emphasizing the need for population-
based care of older adult patients. Ultimately, the project’s fulfillment of AACN DNP Essential 
VI: Interprofessional Collaboration for Improving Patient and Population Health Outcomes 
proved to be most valuable. In this general internal medicine clinic, the intervention promoted an 
opportunity for the evolving role of DNP to collaborate with an interdisciplinary team. This 
scholarly DNP project introduced the integration of Advanced Nursing Practice (AACN DNP 
Essential VIII) with the clinical practice doctorate.  
Conclusion 
 The educational program designed for this intervention is extensive, yet feasible for 
improving outcomes. The information is invaluable to expanding provider knowledge that will 
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augment their practice with evidence-based tools. Comprehensive online modules covered 
essential topics in medication safety, and due to the viability of their virtual platform, prove to be 
an excellent source of knowledge for healthcare providers in all settings. It should be required 
learning for all prescribing practitioners who care for older adults, and demonstration of 
competency is pivotal for guiding practice. The aims of this project were met and successfully 
influenced providers’ behaviors. Clinicians who received the education demonstrated a greater 
confidence deprescribing, as well as an increased knowledge in PIMs. These behavioral 
modifications will ultimately lead to changes in practice that could immensely benefit health 
outcomes of older adult patients.  
In Beers We Trust is a complex project that illustrated the gravity and intricate nature of 
medication safety in older adults. It is imperative that medications are consistently evaluated for 
clinical benefit and risk of harm. When these measures are overlooked, patients are at a 
substantially greater risk of adverse drug events and mortality. As a result, there is a crucial need 
for prescribing practitioners to demonstrate proper judgement and intellectual acuity throughout 
the deprescribing process and management of PIMs in older adults. By educating providers and 
promoting greater accessibility to resources such as the Beers Criteria® and deprescribing tools, 
medical professionals gain the ability to make better-informed clinical decisions which lead to 
safer medication practices. Board-certified geriatric pharmacist Simonson (2019) wrote a column 
in the journal Geriatric Nursing titled, “Deprescribing is not rocket science, but it is 
challenging.” In Beers We Trust is a tremendous testament to this notion, and accordingly, 
demonstrated the critical necessity of provider education. 
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Appendix A 
Theoretical Framework:  
Knowledge-to-Action (KTA) Model 
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Appendix B 
Budget Table 
Description Cost Total Responsible Party 
AGS Beers Criteria® Pocket 
Cards (purchased in sets of 25) 
25 cards = $30 
 
Shipping Cost = 
$14.00 
100 cards = 
$134 
 
Covered under “Love of 
Learning” grant from 
The Honor Society of 
Phi Kappa Phi  
 
(25 cards:  
AGS member price $30;  
regular price $38.99) 
 
Quality color printing from 
Staples of Bruyère drug specific 
deprescribing algorithms 
(3 sheets per provider) 
$1.08 per double-
sided sheet = 
$97.20 for 90 sheets 
90 
providers x 
3 sheets = 
$291 
Covered under “Love of 
Learning” grant from 
The Honor Society of 
Phi Kappa Phi 
Time spent creating educational 
materials (drafting educational 
emails with deprescribing tools 
and Beers Criteria® 
information; creating 
presentations to supplement 
learning) 
RN pay $33.86/ hour 
50 hours = 
$1693 
Paid by DNP student 
Total:   $2,118  
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Appendix C 
Simplified Project Timeline 
Task 
Aug. 
2019 
Sept. 
2019 
Oct. 
2019 
Nov. 
2019 
Dec. 
2019 
Jan. 
2020 
Feb. 
2020 
March 
2020 
April 
2020 
Meet with key stakeholders 
– GIM nurse manager and 
medical director 
X   
 
 
 
 
    
Proposal approval by DNP 
Committee 
 X        
Pre-intervention 
quantitative data of PIM 
trends collected  
 X        
Introduction presentation 
and email sent to all eligible 
licensed independent 
practitioners in GIM clinic 
  X       
Implementation and data 
collection - weekly 
educational emails sent to 
all prescribers on specific 
drug classes on Beers 
Criteria® 
   X X X    
Post-intervention survey 
administered via email 
      X   
Data analysis and 
evaluation of outcomes 
      X X  
Results presented to internal 
medicine clinic and 
administration; consider 
policy change within 
facility 
        X 
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Appendix D: Drug-Specific Algorithms
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Appendix E 
Pre-intervention Survey 
Demographics 
- Generate unique survey ID to ensure confidentiality. The same instructions will be used in a future 
post-intervention survey. 
o What is the first letter of the city you were born in? ___ 
o What day of the month were you born? ___ 
o What is the second letter of your first name? ___ 
Combine your responses to create your ID (eg. W02N) and enter: ____________ 
- What is your current role in the GIM clinic?  
___ attending physician    ____ resident physician     ____ NP    ____ PA     _____ other (please specify) 
 
- How many years have you had prescriptive authority? (Round up to nearest one year): _____ 
 
Knowledge 
- Of the choices below, which medications are on the 2019 Updated American Geriatric 
Society (AGS) Beers Criteria® for Potentially Inappropriate Medication Use in Older 
Adults? (Select all that apply)** 
 
Note** There are many medications on the Beers Criteria® in subcategories for special 
considerations such as exacerbation of certain comorbidities. This question is asking to select 
only medications that are on the general list of medications that are sufficiently unique/ 
particularly problematic for older adults compared to their younger cohorts. 
 
- Famotidine □ 
- Pantoprazole □ 
- Diphenhydramine □ 
- Hydromorphone □ 
- Docusate □ 
- Zolpidem □ 
- Morphine □ 
- Diazepam □ 
- Haloperidol □ 
- Metronidazole □ 
- Atorvastatin □ 
- Nifedipine □ 
- Metoprolol □ 
- Risperidone □ 
- Ibuprofen □ 
- Acetaminophen □ 
- Cyclobenzaprine □ 
- Glimepiride □ 
 
 
- There is controversy in the evidence defining the term "polypharmacy." In your own 
experience, polypharmacy refers to concurrent use of at least how many medications? 
_______ 
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- Which of the following is true regarding the AGS Beers Criteria®? 
a). The purpose is to identify potentially inappropriate medications that should be avoided in all adults 
b.) The goal is to reduce adverse drug events/ drug related problems and improve medication selection/ 
mediation use in older adults 
c.) It is designed for use only in primary care settings, but it is also used as an educational, quality, and 
research tool 
d.) All of the above 
e.) None of the above 
Current Prescribing Practices 
When caring for the older adult patient population (age ≥ 65):  
 
- Do you perform a comprehensive medication reconciliation at the start of each patient visit by 
evaluating the risk and benefit of each individual medication the patient is taking? 
 
____ almost always   ____ frequently ____ occasionally  ____ rarely  ____ never 
 
- Do you consider intentionally deprescribing medications in older adults to reduce polypharmacy? 
____ almost always   ____ frequently ____ occasionally  ____ rarely  ____ never 
 
- Do you utilize the Beers Criteria® as a resource in your practice?  
____ almost always   ____ frequently ____ occasionally  ____ rarely  ____ never 
- Are you interested in receiving evidence-based tools, knowledge, and algorithms that can help you 
to deprescribe potentially inappropriate medications? 
____ extremely interested   ____ very interested ____ somewhat interested 
____ not so interested  ____ not at all interested 
- What is/are the most common potentially inappropriate medication(s) that you see on active 
medication lists of older adults in your practice?  
 
_________________________________________________________________________________ 
 
Self-efficacy* 
This section of the survey is designed to help us gain a better understanding of how clinicians rate their self-
efficacy in deprescribing an older adult (age ≥ 65) patients’ medication(s). Self-efficacy refers to one’s belief 
in their capability to carry out specific tasks. In this case, we are interested in your belief in your capability to 
carry out the tasks related to deprescribing (tapering or stopping) a medication an older adult patient is 
currently taking. using the scale below. Please rate how certain you are right now that you can carry out these 
tasks using the scale below: 
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0  10  20  30  40  50  60  70  80  90  100 
 
Cannot do at all    Moderately certain can do   Highly certain can do 
 
Deprescribing potentially inappropriate medications (PIMs): 
Potentially inappropriate medications are defined by the American Geriatric Society as “medications that pose 
greater risks than they provide in therapeutic value or those medications for which a safer alternative is available.” 
 
For a patient 65 years of age or older who is taking a potentially inappropriate medication, I am able to: 
Item                 Certainty (0-100) 
 
- Weigh the benefits vs. harms of continuing the PIM       ____ 
- Weigh the benefits vs. harms of deprescribing the PIM       ____ 
- Determine whether a non-pharmacological intervention would facilitate deprescribing the PIM  ____ 
- Consider the patient’s preferences, care goals, and life expectancy in deciding                                                       
whether to continue or describe the PIM                     ____  
- Determine the best dosing approach to deprescribing the PIM      ____ 
- Develop a monitoring plan to determine the outcome of deprescribing the PIM    ____ 
- Negotiate a deprescribing plan for the PIM with the patient/caregivers     ____ 
- Monitor and follow-up to determine the outcome of deprescribing the PIM    ____ 
- Determine if PIM tapering should stop or if the PIM should be restarted     ____ 
 
Deprescribing under potentially impeding circumstances: 
A number of situations are described below which can make it difficult to deprescribe medications in older adults. 
 
For a patient 65 years of age or older, I am able to deprescribe a medication:  
Item                 Certainty (0-100) 
 
- When I am concerned about adverse drug withdrawal events      ____ 
- When I am concerned about exacerbations of the underlying condition the drug is being used to treat ____ 
- When disease-specific clinical guidelines recommend the use of a medication    ____ 
- When the medication is coupled to performance indicators      ____ 
- When I receive little support from colleagues for stopping or reducing medications   ____ 
- When I have too much work to do         ____ 
- When I am concerned about damage to my provider-patient relationship    ____ 
- When the patient is resistant to change         ____ 
- When the patient’s family/caregivers are resistant to change      ____ 
- When there is no literature describing the effects of medication tapering or discontinuation ____ 
- When there is no guidance on how to taper or stop a medication     ____ 
- When I am not the original prescriber of the medication       ____ 
- When the medication was prescribed by a specialist       ____ 
- When I am unsure why the medication was started originally       ____ 
- When the medication is being used to treat an adverse effect of another medication   ____ 
 
-  
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- Overall, how comfortable are you deprescribing or adjusting dosages of medications, including 
those that you did not initially prescribe to the patient? 
____ extremely confident   ____ very confident ____ somewhat confident 
____ not so confident  ____ not at all confident 
*These self-efficacy portions of the survey were adapted with permission directly from Dr. Barbara 
Farrell of the Bruyère Research Institute. Completion of this Deprescribing Project will aid in validating 
the psychometric properties of the instrument. The published article with results from the original pilot 
can be found at http://dx.doi.org/10.1016/j.sapharm.2017.01.003 
Bonus Question! 
Is there specific knowledge or information you are hoping to gain from participating in 
this project? 
____________________________________________________________________________________
____________________________________________________________________________________
____________________________________________________________________________________ 
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Appendix F 
Post-intervention Survey 
Demographics 
- Generate unique survey ID to ensure confidentiality. The same instructions will be used in a future 
post-intervention survey. 
o What is the first letter of the city you were born in? ___ 
o What day of the month were you born? ___ 
o What is the second letter of your first name? ___ 
Combine your responses to create your ID (eg. W02N) and enter: ____________ 
- What is your current role in the GIM clinic?  
___ attending physician    ____ resident physician     ____ NP    ____ PA     _____ other (please specify) 
 
- How many years have you had prescriptive authority? (Round up to nearest one year): _____ 
 
Knowledge 
- Of the choices below, which medications are on the 2019 Updated American Geriatric 
Society (AGS) Beers Criteria® for Potentially Inappropriate Medication Use in Older 
Adults? (Select all that apply)** 
 
Note** There are many medications on the Beers Criteria® in subcategories for special 
considerations such as exacerbation of certain comorbidities. This question is asking to select 
only medications that are on the general list of medications that are sufficiently unique/ 
particularly problematic for older adults compared to their younger cohorts. 
 
- Famotidine □ 
- Pantoprazole □ 
- Diphenhydramine □ 
- Hydromorphone □ 
- Docusate □ 
- Zolpidem □ 
- Morphine □ 
- Diazepam □ 
- Haloperidol □ 
- Metronidazole □ 
- Atorvastatin □ 
- Nifedipine □ 
- Metoprolol □ 
- Risperidone □ 
- Ibuprofen □ 
- Acetaminophen □ 
- Cyclobenzaprine □ 
- Glimepiride □ 
 
 
- There is controversy in the evidence defining the term "polypharmacy." In your own 
experience, polypharmacy refers to concurrent use of at least how many medications? 
_______ 
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- Which of the following is true regarding the AGS Beers Criteria®? 
a). The purpose is to identify potentially inappropriate medications that should be avoided in all adults 
b.) The goal is to reduce adverse drug events/ drug related problems and improve medication selection/ 
mediation use in older adults 
c.) It is designed for use only in primary care settings, but it is also used as an educational, quality, and 
research tool 
d.) All of the above 
e.) None of the above 
Current Prescribing Practices 
When caring for the older adult patient population (age ≥ 65):  
 
- Do you perform a comprehensive medication reconciliation at the start of each patient visit by 
evaluating the risk and benefit of each individual medication the patient is taking? 
 
____ almost always   ____ frequently ____ occasionally  ____ rarely  ____ never 
 
- Do you consider intentionally deprescribing medications in older adults to reduce polypharmacy? 
____ almost always   ____ frequently ____ occasionally  ____ rarely  ____ never 
 
- Do you utilize the Beers Criteria® as a resource in your practice?  
____ almost always   ____ frequently ____ occasionally  ____ rarely  ____ never 
- When appropriate, how often do you use the evidence-based tools, knowledge, and/or algorithms for 
deprescribing PIMs in older adults that were given to you during this project? 
____ almost always   ____ frequently ____ occasionally  ____ rarely  ____ never 
 
- What is/are the most common potentially inappropriate medication(s) that you see on active 
medication lists of older adults in your practice?  
 
___________________________________________________________________________________________ 
 
Self-efficacy* 
This section of the survey is designed to help us gain a better understanding of how clinicians rate their self-
efficacy in deprescribing an older adult (age ≥ 65) patients’ medication(s). Self-efficacy refers to one’s belief 
in their capability to carry out specific tasks. In this case, we are interested in your belief in your capability to 
carry out the tasks related to deprescribing (tapering or stopping) a medication an older adult patient is 
currently taking. using the scale below. Please rate how certain you are right now that you can carry out these 
tasks using the scale below: 
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0  10  20  30  40  50  60  70  80  90  100 
 
Cannot do at all    Moderately certain can do   Highly certain can do 
 
Deprescribing potentially inappropriate medications (PIMs): 
Potentially inappropriate medications are defined by the American Geriatric Society as “medications that pose 
greater risks than they provide in therapeutic value or those medications for which a safer alternative is available.” 
 
For a patient 65 years of age or older who is taking a potentially inappropriate medication, I am able to: 
Item                 Certainty (0-100) 
 
- Weigh the benefits vs. harms of continuing the PIM       ____ 
- Weigh the benefits vs. harms of deprescribing the PIM       ____ 
- Determine whether a non-pharmacological intervention would facilitate deprescribing the PIM  ____ 
- Consider the patient’s preferences, care goals, and life expectancy in deciding                                                     
whether to continue or describe the PIM        ____  
- Determine the best dosing approach to deprescribing the PIM      ____ 
- Develop a monitoring plan to determine the outcome of deprescribing the PIM    ____ 
- Negotiate a deprescribing plan for the PIM with the patient/caregivers     ____ 
- Monitor and follow-up to determine the outcome of deprescribing the PIM    ____ 
- Determine if PIM tapering should stop or if the PIM should be restarted     ____ 
 
Deprescribing under potentially impeding circumstances: 
A number of situations are described below which can make it difficult to deprescribe medications in older adults. 
 
For a patient 65 years of age or older, I am able to deprescribe a medication:  
Item                 Certainty (0-100) 
 
- When I am concerned about adverse drug withdrawal events      ____ 
- When I am concerned about exacerbations of the underlying condition the drug is being used to treat ____ 
- When disease-specific clinical guidelines recommend the use of a medication    ____ 
- When the medication is coupled to performance indicators      ____ 
- When I receive little support from colleagues for stopping or reducing medications   ____ 
- When I have too much work to do         ____ 
- When I am concerned about damage to my provider-patient relationship    ____ 
- When the patient is resistant to change         ____ 
- When the patient’s family/caregivers are resistant to change      ____ 
- When there is no literature describing the effects of medication tapering or discontinuation ____ 
- When there is no guidance on how to taper or stop a medication     ____ 
- When I am not the original prescriber of the medication       ____ 
- When the medication was prescribed by a specialist       ____ 
- When I am unsure why the medication was started originally       ____ 
- When the medication is being used to treat an adverse effect of another medication   ____ 
 
-  
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- Overall, how comfortable are you deprescribing or adjusting dosages of medications, including those     
that you did not initially prescribe to the patient? 
____ extremely confident   ____ very confident ____ somewhat confident 
____ not so confident  ____ not at all confident 
*These self-efficacy portions of the survey were adapted with permission directly from Dr. Barbara Farrell of the 
Bruyère Research Institute. Completion of this Deprescribing Project will aid in validating the psychometric 
properties of the instrument. The published article with results from the original pilot can be found at 
http://dx.doi.org/10.1016/j.sapharm.2017.01.003 
Bonus Questions! 
What was the most beneficial resource(s) you received from this project? 
____________________________________________________________________________________ 
What is the most important lesson you learned from this project? 
____________________________________________________________________________________ 
What could have been done to further improve knowledge and practice of deprescribing? 
____________________________________________________________________________________ 
Other comments (optional): 
____________________________________________________________________________________
 
